Cefotaxime and Kayexalate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cefotaxime (cefotaxime sodium) and Kayexalate (sodium polystyrene sulfonate). Common drug interactions include eosinophilia among females and urine output decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Cefotaxime and Kayexalate. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Cefotaxime?

Cefotaxime has active ingredients of cefotaxime sodium. eHealthMe is studying from 7,559 Cefotaxime users. Check the latest studies of Cefotaxime.

What is Kayexalate?

Kayexalate has active ingredients of sodium polystyrene sulfonate. eHealthMe is studying from 5,004 Kayexalate users. Check the latest studies of Kayexalate.

On Aug, 08, 2026

11 people who take Cefotaxime and Kayexalate together, and have interactions are studied.

Cefotaxime and Kayexalate drug interactions.

What are the common drug interactions of Cefotaxime and Kayexalate, by gender? *:

female:

Eosinophilia (eosinophil count in the peripheral blood exceeds)
Hepatocellular injury (liver injury)
Rash generalised (rash on most of body parts)
Dyspnoea (difficult or laboured respiration)
Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)

male:

Urine output decreased
Abdominal distension
Blood osmolarity decreased
Blood osmolarity increased
Blood parathyroid hormone increased
Blood phosphorus decreased
Blood potassium decreased
Blood sodium decreased
Blood urea increased
Carbon dioxide increased

What are the common drug interactions of Cefotaxime and Kayexalate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Cardiac arrest
Cardiac failure
Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
Disease progression
Nervous system disorder (a general class of medical conditions affecting the nervous system)
Osteitis (a general term for inflammation of bone)
Pneumonia
Procedural site reaction

60+:

Eosinophilia (eosinophil count in the peripheral blood exceeds)
Hepatocellular injury (liver injury)
Peripheral arterial occlusive disease (reproducible ischemic muscle pain)
Thrombophlebitis (swelling (inflammation) of a vein caused by a blood clot)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
Linear iga disease (a rare, idiopathic or drug-induced autoimmune blistering disease of skin)
Rash generalised (rash on most of body parts)
Toxic skin eruption (skin breakdown due to toxic substance)
Balance disorder
Dyspnoea (difficult or laboured respiration)

What are the existing conditions these people have? *

Respiratory Tract Infection: 1 person, 9.09%
Rashes (redness): 1 person, 9.09%
Pneumonia: 1 person, 9.09%
Pain: 1 person, 9.09%
Insulin-Requiring Type 2 Diabetes Mellitus: 1 person, 9.09%
Infection: 1 person, 9.09%
Immunodeficiency Disorders: 1 person, 9.09%
Hypouricaemia (level of uric acid in the blood that is abnormally high): 1 person, 9.09%
Hypotension (abnormally low blood pressure): 1 person, 9.09%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cefotaxime and Kayexalate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously